Roche Reports Positive Phase III Results for Multiple Sclerosis Treatment Fenebrutinib

Key Facts

1Fenebrutinib reduced the annualized relapse rate (ARR) by 51% compared to teriflunomide in the FENhance 1 study.

2Results are consistent with the FENhance 2 study which showed a 59% reduction, equating to approximately one relapse every 17 years.

3The study met secondary endpoints showing statistically and clinically meaningful reductions in brain lesions.

Roche announced positive results from its Phase III FENhance 1 study, evaluating the investigational drug fenebrutinib for relapsing multiple sclerosis (RMS). The study demonstrated that fenebrutinib reduced the annualized relapse rate by 51% compared to teriflunomide, confirming its high clinical efficacy. These findings align with the FENhance 2 study, which showed a 59% reduction, effectively translating to approximately one relapse every 17 years. Additionally, the trial met its secondary endpoints, showing statistically significant reductions in brain lesions. As a potential first-in-class BTK inhibitor, fenebrutinib represents a significant advancement in treating both relapsing and primary progressive forms of the disease. Investors view these clinical successes as a strong fundamental driver for Roche's future market position and regulatory approval prospects.